Scenic Biotech

The company's core technology is the proprietary Cell-Seq platform, a functional genomics tool used to identify these genetic modifiers, also known as disease suppressors. This platform creates high-resolution 'disease maps' that profile biological pathways and help uncover novel drug targets. Unlike treatments that target the primary faulty gene, modifier therapy aims to rebalance health by acting on another part of the genome that naturally counteracts the disease's impact. The technology uses special human cells with a single copy of each gene to systematically identify genes that influence disease-causing pathways.

Scenic Biotech's business model involves developing its own pipeline of wholly-owned small molecule programs while also leveraging its Cell-Seq platform through strategic collaborations with major pharmaceutical companies. These partnerships provide upfront payments, milestone fees, and potential royalties, helping to fund internal development. The company has established multi-year agreements with Genentech (a member of the Roche Group), Bristol Myers Squibb, Alnylam Pharmaceuticals, and Ono Pharmaceutical to discover new therapeutic targets.

The company's internal pipeline is focused on severe diseases, including neuro-metabolic and metabolic disorders like Niemann-Pick type C and Barth syndrome, as well as immuno-oncology. Its most advanced program is a small-molecule inhibitor targeting PLA2G15 for rare disorders such as Batten disease and Niemann-Pick type C. Scenic Biotech has raised significant funding, including a Series A round, to advance its programs toward clinical trials.